Literature DB >> 17016468

Progress and prospects: gene transfer into embryonic stem cells.

F Yates1, G Q Daley.   

Abstract

With the isolation of human embryonic stem cells (hESCs) in 1998 came the realization of a long-sought aspiration for an unlimited source of human tissue. The difficulty of differentiating ESCs to pure, clinically exploitable cell populations to treat genetic and degenerative diseases is being solved in part with the help of genetically modified cell lines. With progress in genome editing and somatic cell nuclear transfer, it is theoretically possible to obtain genetically repaired isogenic cells. Moreover, the prospect of being able to select, isolate and expand a single cell to a vast population of cells could achieve a unique level of quality control, until now unattainable in the field of gene therapy. Most of the tools necessary to develop these strategies already exist in the mouse ESC system. We review here the advances accomplished in those fields and present some possible applications to hESC research.

Entities:  

Mesh:

Year:  2006        PMID: 17016468     DOI: 10.1038/sj.gt.3302854

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  14 in total

1.  Nucleofection mediates high-efficiency stable gene knockdown and transgene expression in human embryonic stem cells.

Authors:  Kristi A Hohenstein; April D Pyle; Jing Yi Chern; Leslie F Lock; Peter J Donovan
Journal:  Stem Cells       Date:  2008-03-06       Impact factor: 6.277

2.  An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells.

Authors:  Jae-Hyung Jang; James T Koerber; Jung-Suk Kim; Prashanth Asuri; Tandis Vazin; Melissa Bartel; Albert Keung; Inchan Kwon; Kook In Park; David V Schaffer
Journal:  Mol Ther       Date:  2011-01-11       Impact factor: 11.454

3.  Human embryonic stem cells form functional thyroid follicles.

Authors:  Risheng Ma; Rauf Latif; Terry F Davies
Journal:  Thyroid       Date:  2015-02-06       Impact factor: 6.568

4.  Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells.

Authors:  Prashanth Asuri; Melissa A Bartel; Tandis Vazin; Jae-Hyung Jang; Tiffany B Wong; David V Schaffer
Journal:  Mol Ther       Date:  2011-11-22       Impact factor: 11.454

5.  Gene editing of human embryonic stem cells via an engineered baculoviral vector carrying zinc-finger nucleases.

Authors:  Yuning Lei; Chi-Lin Lee; Kye-Il Joo; Jonathan Zarzar; Yarong Liu; Bingbing Dai; Victoria Fox; Pin Wang
Journal:  Mol Ther       Date:  2011-02-15       Impact factor: 11.454

6.  High-efficiency transient transduction of human embryonic stem cell-derived neurons with baculoviral vectors.

Authors:  Jieming Zeng; Juan Du; Jiakai Lin; Xiao Ying Bak; Chunxiao Wu; Shu Wang
Journal:  Mol Ther       Date:  2009-06-16       Impact factor: 11.454

7.  Genetic manipulation of neural progenitors derived from human embryonic stem cells.

Authors:  Sujoy K Dhara; Brian A Gerwe; Anirban Majumder; Mahesh C Dodla; Nolan L Boyd; David W Machacek; Kowser Hasneen; Steven L Stice
Journal:  Tissue Eng Part A       Date:  2009-11       Impact factor: 3.845

8.  A targeted neuroglial reporter line generated by homologous recombination in human embryonic stem cells.

Authors:  Haipeng Xue; Sen Wu; Sophia T Papadeas; Steve Spusta; Anna Maria Swistowska; Chad C MacArthur; Mark P Mattson; Nicholas J Maragakis; Mario R Capecchi; Mahendra S Rao; Xianmin Zeng; Ying Liu
Journal:  Stem Cells       Date:  2009-08       Impact factor: 6.277

9.  Nanoparticles for gene transfer to human embryonic stem cell colonies.

Authors:  Jordan J Green; Betty Y Zhou; Maisam M Mitalipova; Caroline Beard; Robert Langer; Rudolf Jaenisch; Daniel G Anderson
Journal:  Nano Lett       Date:  2008-08-29       Impact factor: 11.189

Review 10.  Electrospun Nanofibers for Cancer Therapy.

Authors:  Huanhuan Luo; Tianyang Jie; Li Zheng; Chenglong Huang; Gang Chen; Wenguo Cui
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.